{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:34:09Z","timestamp":1792791249307,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Frankfurter Stiftung f\u00fcr krebskranke Kinder Hilfe f\u00fcr krebskranke Kinder Frankfurt e.V.","id":[{"id":"https:\/\/ror.org\/02ecj1n50","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The nucleoside analogue nelarabine, the prodrug of arabinosylguanine (AraG), is effective against T-cell acute lymphoblastic leukaemia (T-ALL) but not against B-cell ALL (B-ALL). The underlying mechanisms have remained elusive. Here, data from pharmacogenomics studies and a panel of ALL cell lines reveal an inverse correlation between nelarabine sensitivity and the expression of\n                    <jats:italic>SAMHD1<\/jats:italic>\n                    , which can hydrolyse and inactivate triphosphorylated nucleoside analogues. Lower SAMHD1 abundance is detected in T-ALL than in B-ALL in cell lines and patient-derived leukaemic blasts. Mechanistically, T-ALL cells display increased\n                    <jats:italic>SAMHD1<\/jats:italic>\n                    promoter methylation without increased global DNA methylation. SAMHD1 depletion sensitises B-ALL cells to AraG, while ectopic SAMHD1 expression in SAMHD1-null T-ALL cells induces AraG resistance. SAMHD1 has a larger impact on nelarabine\/AraG than on cytarabine in ALL cells. Opposite effects are observed in acute myeloid leukaemia cells, indicating entity-specific differences. In conclusion,\n                    <jats:italic>SAMHD1<\/jats:italic>\n                    promoter methylation and, in turn,\n                    <jats:italic>SAMHD1<\/jats:italic>\n                    expression levels determine ALL cell response to nelarabine.\n                  <\/jats:p>","DOI":"10.1038\/s42003-020-1052-8","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T06:02:52Z","timestamp":1592978572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine"],"prefix":"10.1038","volume":"3","author":[{"given":"Tamara","family":"Rothenburger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie-May","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-9432","authenticated-orcid":false,"given":"Tobias","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rothweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-0498","authenticated-orcid":false,"given":"Andrew","family":"Feber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4737-8233","authenticated-orcid":false,"given":"Tim R.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-6479","authenticated-orcid":false,"given":"Mark N.","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver T.","family":"Keppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5710-5888","authenticated-orcid":false,"given":"Martin","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-2087","authenticated-orcid":false,"suffix":"Jr.","given":"Jindrich","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"1052_CR1","first-page":"29","volume":"8","author":"M Mohseni","year":"2018","unstructured":"Mohseni, M., Uludag, H. & Brandwein, J. M. Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. Am. J. Blood Res 8, 29\u201356 (2018).","journal-title":"Am. J. Blood Res"},{"key":"1052_CR2","doi-asserted-by":"publisher","first-page":"E2929","DOI":"10.3390\/ijms20122929","volume":"20","author":"N Coccaro","year":"2019","unstructured":"Coccaro, N., Anelli, L., Zagaria, A., Specchia, G. & Albano, F. Next-Generation sequencing in acute lymphoblastic leukemia. Int. J. Mol. Sci. 20, E2929 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1052_CR3","doi-asserted-by":"publisher","first-page":"E3021","DOI":"10.3390\/ijms20123021","volume":"20","author":"E Follini","year":"2019","unstructured":"Follini, E., Marchesini, M. & Roti, G. Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia. Int. J. Mol. Sci. 20, E3021 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1052_CR4","doi-asserted-by":"publisher","first-page":"E191","DOI":"10.3390\/genes10030191","volume":"10","author":"S Pavlovic","year":"2019","unstructured":"Pavlovic, S. et al. Pharmacogenomic and pharmacotranscriptomic profiling of childhood acute lymphoblastic leukemia: paving the way to personalized treatment. Genes (Basel) 10, E191 (2019).","journal-title":"Genes (Basel)"},{"key":"1052_CR5","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood.V61.4.660.660","volume":"61","author":"A Cohen","year":"1983","unstructured":"Cohen, A., Lee, J. W. & Gelfand, E. W. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 61, 660\u2013666 (1983).","journal-title":"Blood"},{"key":"1052_CR6","first-page":"6498","volume":"49","author":"DS Shewach","year":"1989","unstructured":"Shewach, D. S. & Mitchell, B. S. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells. Cancer Res. 49, 6498\u20136502 (1989).","journal-title":"Cancer Res."},{"key":"1052_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour, E. et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 16, 1547\u20131555 (2015).","journal-title":"Lancet Oncol."},{"key":"1052_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474086.2017.1262757","volume":"10","author":"TM Kadia","year":"2017","unstructured":"Kadia, T. M. & Gandhi, V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert. Rev. Hematol. 10, 1\u20138 (2017).","journal-title":"Expert. Rev. Hematol."},{"key":"1052_CR9","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian, H. M. et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 4, e387\u2013e398 (2017).","journal-title":"Lancet Haematol."},{"key":"1052_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","volume":"129","author":"DI Marks","year":"2017","unstructured":"Marks, D. I. & Rowntree, C. Management of adults with T-cell lymphoblastic leukemia. Blood 129, 1134\u20131142 (2017).","journal-title":"Blood"},{"key":"1052_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/bjh.14874","volume":"179","author":"CM Zwaan","year":"2017","unstructured":"Zwaan, C. M. et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br. J. Haematol. 179, 284\u2013293 (2017).","journal-title":"Br. J. Haematol."},{"key":"1052_CR12","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","volume":"5","author":"E Jabbour","year":"2018","unstructured":"Jabbour, E. et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 5, e618\u2013e627 (2018).","journal-title":"Lancet Haematol."},{"key":"1052_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood.2019001557","volume":"135","author":"DT Teachey","year":"2020","unstructured":"Teachey, D. T. & O\u2019Connor, D. How i treat newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma in children. Blood 135, 159\u2013166 (2020).","journal-title":"Blood"},{"key":"1052_CR14","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","volume":"23","author":"SL Berg","year":"2005","unstructured":"Berg, S. L. et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group. J. Clin. Oncol. 23, 3376\u20133382 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1052_CR15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151\u20131161 (2013).","journal-title":"Cell"},{"key":"1052_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"1052_CR17","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"1052_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1365-2141.2007.06527.x","volume":"137","author":"AH Beesley","year":"2007","unstructured":"Beesley, A. H. et al. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 137, 109\u2013116 (2007).","journal-title":"Br. J. Haematol."},{"key":"1052_CR19","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1182\/blood-2011-02-337840","volume":"118","author":"I Homminga","year":"2011","unstructured":"Homminga, I. et al. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood 118, 2184\u20132190 (2011).","journal-title":"Blood"},{"key":"1052_CR20","doi-asserted-by":"publisher","first-page":"D419","DOI":"10.1093\/nar\/gky1038","volume":"47","author":"H Mi","year":"2019","unstructured":"Mi, H., Muruganujan, A., Ebert, D., Huang, X. & Thomas, P. D. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 47, D419\u2013D426 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1052_CR21","doi-asserted-by":"publisher","first-page":"20683","DOI":"10.1074\/jbc.M113.472159","volume":"288","author":"SM Amie","year":"2013","unstructured":"Amie, S. M. et al. Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. J. Biol. Chem. 288, 20683\u201320691 (2013).","journal-title":"J. Biol. Chem."},{"key":"1052_CR22","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1128\/AAC.03145-14","volume":"58","author":"E Ballana","year":"2014","unstructured":"Ballana, E. et al. SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 58, 4804\u20134813 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1052_CR23","doi-asserted-by":"publisher","first-page":"e0169052","DOI":"10.1371\/journal.pone.0169052","volume":"12","author":"JA Hollenbaugh","year":"2017","unstructured":"Hollenbaugh, J. A. et al. Substrates and Inhibitors of SAMHD1. PLoS ONE 12, e0169052 (2017).","journal-title":"PLoS ONE"},{"key":"1052_CR24","doi-asserted-by":"publisher","first-page":"E10022","DOI":"10.1073\/pnas.1805593115","volume":"115","author":"KM Knecht","year":"2018","unstructured":"Knecht, K. M. et al. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1. Proc. Natl Acad. Sci. USA 115, E10022\u2013E10031 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1052_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/08916934.2018.1454912","volume":"51","author":"CH Mauney","year":"2018","unstructured":"Mauney, C. H. & Hollis, T. SAMHD1: recurring roles in cell cycle, viral restriction, cancer, and innate immunity. Autoimmunity 51, 96\u2013110 (2018).","journal-title":"Autoimmunity"},{"key":"1052_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/15384101.2017.1314407","volume":"16","author":"N Herold","year":"2017","unstructured":"Herold, N. et al. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell Cycle 16, 1029\u20131038 (2017).","journal-title":"Cell Cycle"},{"key":"1052_CR27","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMc1412123","volume":"371","author":"T Herold","year":"2014","unstructured":"Herold, T., Baldus, C. D. & G\u00f6kbuget, N. Ph-like acute lymphoblastic leukemia in older adults. N. Engl. J. Med 371, 2235 (2014).","journal-title":"N. Engl. J. Med"},{"key":"1052_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3324\/haematol.2015.136366","volume":"102","author":"T Herold","year":"2017","unstructured":"Herold, T. et al. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica 102, 130\u2013138 (2017).","journal-title":"Haematologica"},{"key":"1052_CR29","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1158\/0008-5472.CAN-16-2548","volume":"77","author":"CD Drenberg","year":"2017","unstructured":"Drenberg, C. D. et al. OCTN1 is a high-affinity carrier of nucleoside analogues. Cancer Res. 77, 2102\u20132111 (2017).","journal-title":"Cancer Res."},{"key":"1052_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nm.4255","volume":"23","author":"C Schneider","year":"2017","unstructured":"Schneider, C. et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat. Med. 23, 250\u2013255 (2017).","journal-title":"Nat. Med."},{"key":"1052_CR31","first-page":"447","volume":"2","author":"M Michaelis","year":"2019","unstructured":"Michaelis, M., Wass, M. N. & Cinatl, J. Jr. Drug-adapted cancer cell lines as preclinical models of acquired resistance. Cancer Drug Resist 2, 447\u2013456 (2019).","journal-title":"Cancer Drug Resist"},{"key":"1052_CR32","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1016\/j.jmb.2016.05.025","volume":"428","author":"A Radhakrishnan","year":"2016","unstructured":"Radhakrishnan, A. & Green, R. Connections underlying translation and mRNA stability. J. Mol. Biol. 428, 3558\u20133564 (2016).","journal-title":"J. Mol. Biol."},{"key":"1052_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1042\/BST20160243","volume":"45","author":"AA Bicknell","year":"2017","unstructured":"Bicknell, A. A. & Ricci, E. P. When mRNA translation meets decay. Biochem. Soc. Trans. 45, 339\u2013351 (2017).","journal-title":"Biochem. Soc. Trans."},{"key":"1052_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-biochem-061516-044908","volume":"86","author":"I Dikic","year":"2017","unstructured":"Dikic, I. Proteasomal and autophagic degradation systems. Annu. Rev. Biochem. 86, 193\u2013224 (2017).","journal-title":"Annu. Rev. Biochem."},{"key":"1052_CR35","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.3748\/wjg.v24.i48.5454","volume":"24","author":"RI Ja\u00e9n","year":"2018","unstructured":"Ja\u00e9n, R. I., Prieto, P., Casado, M., Mart\u00edn-Sanz, P. & Bosc\u00e1, L. Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer: an update. World J. Gastroenterol. 24, 5454\u20135461 (2018).","journal-title":"World J. Gastroenterol."},{"key":"1052_CR36","doi-asserted-by":"publisher","first-page":"e46666","DOI":"10.15252\/embr.201846666","volume":"19","author":"PJ Ko","year":"2018","unstructured":"Ko, P. J. & Dixon, S. J. Protein palmitoylation and cancer. EMBO Rep. 19, e46666 (2018).","journal-title":"EMBO Rep."},{"key":"1052_CR37","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/1873-3468.13109","volume":"592","author":"DH Wolf","year":"2018","unstructured":"Wolf, D. H. & Menssen, R. Mechanisms of cell regulation - proteolysis, the big surprise. FEBS Lett. 592, 2515\u20132524 (2018).","journal-title":"FEBS Lett."},{"key":"1052_CR38","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2013-04-490847","volume":"123","author":"R Clifford","year":"2014","unstructured":"Clifford, R. et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 123, 1021\u20131031 (2014).","journal-title":"Blood"},{"key":"1052_CR39","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1073\/pnas.1519128113","volume":"113","author":"M Rentoft","year":"2016","unstructured":"Rentoft, M. et al. Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance. Proc. Natl Acad. Sci. USA 113, 4723\u20134728 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1052_CR40","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2174\/157488706778250104","volume":"1","author":"S Curbo","year":"2006","unstructured":"Curbo, S. & Karlsson, A. Nelarabine: a new purine analog in the treatment of hematologic malignancies. Rev. Recent Clin. Trials 1, 185\u2013192 (2006).","journal-title":"Rev. Recent Clin. Trials"},{"key":"1052_CR41","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1038\/nm.2964","volume":"18","author":"HM Baldauf","year":"2012","unstructured":"Baldauf, H. M. et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat. Med 18, 1682\u20131687 (2012).","journal-title":"Nat. Med"},{"key":"1052_CR42","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nature10195","volume":"474","author":"K Hrecka","year":"2011","unstructured":"Hrecka, K. et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474, 658\u2013661 (2011).","journal-title":"Nature"},{"key":"1052_CR43","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nature10117","volume":"474","author":"N Laguette","year":"2011","unstructured":"Laguette, N. et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474, 654\u2013657 (2011).","journal-title":"Nature"},{"key":"1052_CR44","doi-asserted-by":"publisher","first-page":"9284","DOI":"10.1074\/jbc.M112.447201","volume":"288","author":"S de Silva","year":"2013","unstructured":"de Silva, S. et al. Promoter methylation regulates SAMHD1 gene expression in human CD4+ T cells. J. Biol. Chem. 288, 9284\u20139292 (2013).","journal-title":"J. Biol. Chem."},{"key":"1052_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11413-4","volume":"10","author":"T Oellerich","year":"2019","unstructured":"Oellerich, T. et al. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. Nat. Commun. 10, 3475 (2019).","journal-title":"Nat. Commun."},{"key":"1052_CR46","first-page":"3646","volume":"45","author":"V Verhoef","year":"1985","unstructured":"Verhoef, V. & Fridland, A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res. 45, 3646\u20133650 (1985).","journal-title":"Cancer Res."},{"key":"1052_CR47","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/hon.2654","volume":"37","author":"K Akahane","year":"2019","unstructured":"Akahane, K. et al. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia. Hematol. Oncol. 37, 516\u2013519 (2019).","journal-title":"Hematol. Oncol."},{"key":"1052_CR48","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.celrep.2017.08.008","volume":"20","author":"W Daddacha","year":"2017","unstructured":"Daddacha, W. et al. SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. Cell Rep. 20, 1921\u20131935 (2017).","journal-title":"Cell Rep."},{"key":"1052_CR49","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.critrevonc.2018.04.002","volume":"126","author":"C Wu","year":"2018","unstructured":"Wu, C. & Li, W. Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia. Crit. Rev. Oncol. Hematol. 126, 100\u2013111 (2018).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1052_CR50","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M17-2832","volume":"169","author":"SW Luoh","year":"2018","unstructured":"Luoh, S. W. & Flaherty, K. T. When tissue is no longer the issue: tissue-agnostic cancer therapy comes of age. Ann. Intern. Med. 169, 233\u2013239 (2018).","journal-title":"Ann. Intern. Med."},{"key":"1052_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cell.2019.02.049","volume":"177","author":"FW Huang","year":"2019","unstructured":"Huang, F. W. & Feng, F. Y. A tumor-agnostic NTRK (TRK) Inhibitor. Cell 177, 8 (2019).","journal-title":"Cell"},{"key":"1052_CR52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"1052_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-015-0229-6","volume":"12","author":"S Wittmann","year":"2015","unstructured":"Wittmann, S. et al. Phosphorylation of murine SAMHD1 regulates its antiretroviral activity. Retrovirology 12, 103 (2015).","journal-title":"Retrovirology"},{"key":"1052_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55\u201363 (1983).","journal-title":"J. Immunol. Methods"},{"key":"1052_CR55","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3762\/bjnano.10.166","volume":"10","author":"H Onafuye","year":"2019","unstructured":"Onafuye, H. et al. Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells. Beilstein J. Nanotechnol. 10, 1707\u20131715 (2019).","journal-title":"Beilstein J. Nanotechnol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-1052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-1052-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-1052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T04:56:03Z","timestamp":1723092963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-1052-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1038\/s42003-020-1052-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/863183","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"31 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Johann Wolfgang Goethe University has filed a patent application, on which T.O., C.S., O.T.K. and J.C. are listed as inventors. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"324"}}